164 related articles for article (PubMed ID: 11131964)
1. Teicoplanin Chemistry and Microbiology.
Parenti F; Schito GC; Courvalin P
J Chemother; 2000 Nov; 12 Suppl 5():5-14. PubMed ID: 11131964
[TBL] [Abstract][Full Text] [Related]
2. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
5. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
Cormican MG; Erwin ME; Jones RN
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):241-8. PubMed ID: 9458981
[TBL] [Abstract][Full Text] [Related]
6. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
Jones ME; Gesu G; Ortisi G; Sahm DF; Critchley IA; Goglio A;
Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
8. Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci.
Szűcs Z; Bereczki I; Csávás M; Rőth E; Borbás A; Batta G; Ostorházi E; Szatmári R; Herczegh P
J Antibiot (Tokyo); 2017 May; 70(5):664-670. PubMed ID: 28144040
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Streit JM; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
Grüneberg RN; Hryniewicz W
Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
[TBL] [Abstract][Full Text] [Related]
11. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.
Malabarba A; Ciabatti R; Scotti R; Goldstein BP; Ferrari P; Kurz M; Andreini BP; Denaro M
J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
Bezian MC; Ribou G; Masquelier B
Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of the VITEK 2 system to detect glycopeptide resistance in enterococci.
van Den Braak N; Goessens W; van Belkum A; Verbrugh HA; Endtz HP
J Clin Microbiol; 2001 Jan; 39(1):351-3. PubMed ID: 11136798
[TBL] [Abstract][Full Text] [Related]
15. Glycopeptide tolerance in bacteria causing endocarditis.
Perry JD; Jones AL; Gould FK
J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of teicoplanin against gram-positive cocci.
Allouch P; Pina P; Chaplain C; Delarbre JM; Geffroy F; Grasmick CP; Marcolin M; Morel A; Pangon B; Rio Y; Sédaillan A
Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
[TBL] [Abstract][Full Text] [Related]
17. Glycopeptide and lipoglycopeptide antibiotics.
Kahne D; Leimkuhler C; Lu W; Walsh C
Chem Rev; 2005 Feb; 105(2):425-48. PubMed ID: 15700951
[No Abstract] [Full Text] [Related]
18. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
Chisari G
Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
[TBL] [Abstract][Full Text] [Related]
19. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
Brown DF; Courvalin P
Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
[TBL] [Abstract][Full Text] [Related]
20. Glycopeptide antibiotics: from conventional molecules to new derivatives.
Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]